Cinqair
Named-patient access overview. Cinqair is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cinqair (reslizumab) is a humanised anti-interleukin-5 (IL-5) monoclonal antibody marketed by Teva Pharmaceuticals. The US Food and Drug Administration approved Cinqair in March 2016 as add-on maintenance therapy for adult patients with severe asthma and an eosinophilic phenotype. Cinqair is administered by a healthcare professional as a weight-based intravenous infusion (3 mg/kg) once every four weeks in an infusion centre or hospital outpatient setting. The product is typically initiated and overseen by a pulmonologist or allergist with eosinophilic-asthma experience. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cinqair
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cinqair is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Cinqair in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cinqair
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.